Back to top
more

Fulgent Genetics (FLGT)

(Delayed Data from NSDQ)

$20.01 USD

20.01
136,343

-0.17 (-0.84%)

Updated Jul 9, 2024 04:00 PM ET

After-Market: $20.03 +0.02 (0.10%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Is Bio-Rad Laboratories (BIO) Outperforming Other Medical Stocks This Year?

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Surging Earnings Estimates Signal Upside for Fullgent Genetics (FLGT) Stock

Fullgent Genetics (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Best Momentum Stocks to Buy for November 19th

AOSL, FLGT, AMRC, and SAIA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 19, 2021.

New Strong Buy Stocks for November 19th

AOSL, FLGT, LAZY, MATX, and SCHN have been added to the Zacks Rank #1 (Strong Buy) List on November 19, 2021.

Fullgent Genetics (FLGT) Crossed Above the 200-Day Moving Average: What That Means for Investors

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

New Strong Buy Stocks for November 11th

BLDR, FLGT, MRBK, CC, and NMRK have been added to the Zacks Rank #1 (Strong Buy) List on November 11th.

Fullgent Genetics (FLGT) Surpasses Q3 Earnings Estimates

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 202.31% and -13.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics (FLGT) to Post Q3 Earnings: What's in Store?

The recent buyout of CSI Laboratories and strategic investments in early cancer screening are likely to have contributed to growth for Fulgent Genetics (FLGT).

Earnings Preview: Fullgent Genetics (FLGT) Q3 Earnings Expected to Decline

Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Value Investors Buy Fullgent Genetics (FLGT) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is FULGENT GENETIC (FLGT) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

New Strong Sell Stocks for August 17th

ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.

FULGENT GENETIC (FLGT) Q2 Earnings and Revenues Miss Estimates

FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of -0.78% and -21.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

FULGENT GENETIC (FLGT) Gains But Lags Market: What You Should Know

In the latest trading session, FULGENT GENETIC (FLGT) closed at $110.87, marking a +0.33% move from the previous day.

What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?

Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.

FULGENT GENETIC (FLGT) Reports Next Week: Wall Street Expects Earnings Growth

FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know

In the latest trading session, FULGENT GENETIC (FLGT) closed at $92.25, marking a +0.36% move from the previous day.

FULGENT GENETIC (FLGT) Stock Moves -0.13%: What You Should Know

FULGENT GENETIC (FLGT) closed the most recent trading day at $85.94, moving -0.13% from the previous trading session.

FULGENT GENETIC (FLGT) Stock Sinks As Market Gains: What You Should Know

FULGENT GENETIC (FLGT) closed at $87.17 in the latest trading session, marking a -0.31% move from the prior day.

FULGENT GENETIC (FLGT) Outpaces Stock Market Gains: What You Should Know

FULGENT GENETIC (FLGT) closed at $83.53 in the latest trading session, marking a +1.17% move from the prior day.

FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know

In the latest trading session, FULGENT GENETIC (FLGT) closed at $75.69, marking a +1.16% move from the previous day.

FULGENT GENETIC (FLGT) Gains As Market Dips: What You Should Know

In the latest trading session, FULGENT GENETIC (FLGT) closed at $84, marking a +0.1% move from the previous day.

FULGENT GENETIC (FLGT) Q1 Earnings and Revenues Surpass Estimates

FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 10.02% and 13.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?